DoD tests AI models that make it easy to switch from vendors like Palantir
AUSTIN, Texas—Michael Burkes Brophy, Chief Financial Officer of Natera, Inc. (NASDAQ:NTRA), a $19.55 billion market cap company with a GREAT financial health score according to InvestingPro, recently sold shares of the company’s stock valued at $88,784, according to a regulatory filing. The transactions took place on April 21, 2025, involving the sale of 610 shares at prices ranging from $145.54 to $146.16 per share. The stock has shown remarkable strength, delivering a 58.85% return over the past year despite its characteristic volatility.
In a separate transaction on April 20, Brophy acquired 1,521 shares of common stock through the vesting of Restricted Stock Units (RSUs) at no cost. The RSUs, which convert into common stock on a one-to-one basis, were part of a pre-arranged trading plan to cover tax obligations related to the vesting process.
Following these transactions, Brophy holds a total of 76,468 shares of Natera’s common stock. The sales were conducted under a Rule 10b5-1 trading plan, a common practice among executives to manage stock transactions in compliance with insider trading regulations.
In other recent news, Natera Inc . reported its fourth-quarter 2024 earnings, surpassing Wall Street expectations with revenue reaching $476 million, a 53% increase year-over-year. The company also improved its gross margins to 63% from 51% the previous year, generating $46 million in cash flow during the quarter. TD Cowen and Canaccord Genuity both maintained their Buy ratings for Natera, with Canaccord raising its price target to $195, reflecting confidence in the company’s future growth prospects. Analysts highlighted Natera’s strategic investments in sales and marketing as well as the anticipated rise in Signatera’s price and volume as key growth drivers. Additionally, Natera has initiated the HEROES clinical trial in France to explore therapy de-escalation in metastatic HER2+ breast cancer patients. This trial, sponsored by Unicancer and funded by the French Ministry of Health, aims to measure 1-year progression-free survival in patients testing negative for circulating tumor DNA using Natera’s Signatera test. The company’s fourth-quarter results and ongoing clinical trials underscore its strong position in the personalized genetic testing and diagnostics market.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.